A chemical messenger best known for shaping mood may also help decide when a diseased heart valve fails. Researchers have linked serotonin signaling and a common genetic variant to faster progression of degenerative mitral regurgitation, one of the most frequent heart valve diseases. The work suggests that patients on SSRIs who carry a particular version of the serotonin transporter gene tend to need valve surgery at a younger age.
The finding pulls a well-worn psychiatric drug class into a cardiology conversation — carefully. The researchers stress that SSRIs remain safe for most people. The risk they describe applies to a specific slice of patients whose mitral valves are already breaking down.
A one-way gate that starts to leak
The mitral valve sits between the left atrium and the left ventricle. With each heartbeat, it should snap shut and stop oxygen-rich blood from washing back into the upper chamber. In degenerative mitral regurgitation, or DMR, the thin flaps of that valve thicken, stretch, and lose their crisp geometry. Blood leaks the wrong way. Pressure builds toward the lungs. The heart works harder to push the same volume forward.
Early on, many patients feel nothing. Later come fatigue, breathlessness, atrial fibrillation, and eventually heart failure. Drugs can blunt symptoms, but they do not repair the tissue. If the degeneration of the mitral valve becomes severe, surgery to repair or replace the valve is needed.
Why serotonin turned up in a heart study
Serotonin is a chemical messenger with jobs scattered across the body — mood, sleep, digestion, memory, clotting. Cells receive its signal through surface receptors. A protein called the serotonin transporter, or SERT, then pulls serotonin back inside the cell, ending the signal. SSRIs, including fluoxetine (Prozac) and sertraline (Zoloft), block that reuptake step so serotonin lingers longer in the synapse.
That mechanism is useful in the brain. The Columbia team wanted to know what it might do in a mitral valve that was already sick.
What the 9,000-patient review showed
The researchers reviewed clinical records from patients who had undergone mitral valve repair or replacement for DMR, and they examined valve biopsies collected across collaborating institutions. Patients on SSRIs tended to reach severe regurgitation — the point where surgery becomes necessary — at younger ages than patients who were not taking the drugs.
The data showed taking SSRIs was associated with severe mitral regurgitation that needed surgery at a younger age than in patients not taking SSRIs.
An association is not a cause. Depression, anxiety, and the medications used to treat them travel with other health differences that observational data cannot fully account for. So the team went looking for a mechanism.
Mice, cells, and thickened valves
In the laboratory, transgenic mice engineered to lack the SERT gene developed thicker mitral valves. Normal mice dosed with high levels of SSRIs did the same. Human valve cells grown in dishes told a matching story: low SERT activity pushed the cells to churn out more collagen. Collagen normally gives tissue its structure, but too much of it makes a delicate valve leaflet stiff and misshapen.
The team examined 5-HTTLPR, a DNA variant that affects serotonin transporter activity. Patients with certain variants showed higher rates of valve surgery, and their valve cells showed stronger reactions to serotonin in laboratory tests.
Put together, the pieces sketch a compound risk: an already-degenerating valve, a genetic setup that dampens SERT activity, and a drug that dampens it further.
Healthy valves appeared unaffected
A key caveat runs through the results. Cells taken from healthy human mitral valves did not show harmful effects at normal SSRI doses, and neither did healthy cells carrying the long-long variant. A healthy mitral valve can probably tolerate low SERT activity without deforming and it is unlikely low SERT alone can cause degeneration of the mitral valve. SSRIs are generally safe for most patients — but once the valve has started to degenerate, it may become more susceptible to serotonin and low transporter activity.
That distinction matters clinically. Roughly one in eight U.S. adults takes an antidepressant, and abrupt discontinuation carries its own risks. The researchers are not recommending that anyone stop treatment. They are proposing that a subset of cardiac patients might benefit from knowing their genotype.
Could a cheek swab guide valve surgery?
The researchers suggest that people diagnosed with DMR could be tested for 5-HTTLPR using a blood sample or a mouth swab. In principle, patients with the long-long variant might warrant closer echocardiographic monitoring, earlier surgical planning, or a conversation with their prescribing clinician about switching antidepressant classes if their valve disease is progressing.
Assessing patients with DMR for low SERT activity may help identify patients who may need mitral valve surgery earlier. Prompt repair of a leaky valve could protect the heart and prevent congestive heart failure.
That is a proposal, not a guideline. Current cardiology practice evaluates valve disease through symptoms, imaging, leak severity, and how the heart and lungs are coping with the strain. Adding a genetic test would require the kind of evidence that regulators and specialty societies typically demand — comparative studies showing that the test changes decisions and improves outcomes. The framework for such evaluation has been developed by organizations like the Evaluation of Genomic Applications in Practice and Prevention Working Group, which reviews genetic tests for analytic validity, clinical validity, and clinical utility before endorsing broader use.
Serotonin’s growing footprint in valve disease
Other work has expanded the serotonin-valve story. One study reported that mice with deficient SERT activity were more prone to fibrotic changes in their cardiac valves and in the left ventricular muscle, and it pointed to a serotonin receptor called HTR2B as a driver of the damaging response.
Another investigation looked at a different valve entirely. In a comparison of 38 people with severe aortic stenosis and 38 matched controls, patients with the stiffened, narrowed aortic valve had higher blood levels of serotonin and its main breakdown product. The sample was small and cross-sectional, so it could not sort cause from consequence, but it hinted that serotonin signaling is not limited to the mitral side of the heart.
Additional work examined valve tissue from patients undergoing replacement for severe aortic stenosis alongside normal donor valves. Diseased valves showed reduced SERT expression and stronger serotonin receptor signaling. An experimental compound that blocked HTR2B helped preserve valve structure in mice during an early stage of fibrotic remodeling — an intriguing drug target, though nowhere near clinical use.
What the finding does and does not mean
The Columbia work reshuffles a familiar question: why do some patients with DMR deteriorate faster than others? Age, valve anatomy, and blood pressure explain part of the variation. Genetics governing a serotonin transporter may explain another slice, particularly in people already taking a drug that acts on the same protein.
For readers on SSRIs, the practical takeaway is narrow. If you have been diagnosed with a degenerating mitral valve, this is a conversation worth having with a cardiologist and a prescribing clinician. If your valves are healthy, the current evidence does not point to a hidden risk from your antidepressant.
The bigger scientific point is subtler. A molecule long treated as a brain chemical is turning up in the connective tissue of the heart, shaping how a small flap of collagen holds its shape under pressure. Whether that insight becomes a cheek-swab test in a cardiology clinic depends on trials that have not yet been run.